Tag
FIDSON HEALTHCARE PLC
News and analysis about Fidson Healthcare Plc
So far in 2025, Fidson has delivered a 177% YtD gain, the best in the sector. May & Baker, with a still impressive 86.2% YtD return, is lagging relatively.
Fidson Healthcare Plc has signed a memorandum of understanding to expand its partnership with Japanese firm, Ohara Pharmaceutical Co. Ltd.
In a significant move set to transform Africa’s healthcare landscape, a delegation from Nigeria’s leading pharmaceutical manufacturer, Fidson Healthcare Plc, has announced a deepened strategic alliance with Japanese firm, Ohara Pharmaceutical Co., Ltd.
In this interview with Nairametrics, Dr Ayebae says he has been inspired by his friend, Aliko Dangote, as he reveals what's next for the pharmaceutical company.
Fidson Healthcare Plc has unveiled an ambitious plan to invest $50 million over the next three years, leveraging equity and debt financing to drive both domestic scale and international expansion in pharmaceuticals.
Fidson Healthcare Plc has released its financial results for the first quarter ended 31st March 2025, reporting a pre-tax profit of N4.8 billion.
Shares of Fidson Healthcare Plc rose by 24% in the first week of February 2025, with a trading volume of 8.8 million shares, securing a spot on the NGX’s advancers list for the week.
Nigeria’s leading pharmaceutical company, Fidson Healthcare Plc announces the appointment of three new Directors. This strategic move, made...
Fidson Healthcare Plc’s stock dropped to a 52-week low of N12.5 per share at the start of trading on August 26, 2024, marking a significant 25% decline from its year-end high of N17 recorded in December 2023.
During the company’s Annual General Meeting on July 4, 2024, its shareholders approved the resolution which authorizes its directors to raise N20 billion through a share offering programme.
Fidson Healthcare Plc posted a pre-tax profit of N5.9 billion in FY 2023, representing a marginal 2.4% increase from the N5.8 billion posted in 2022.
Foremost Nigerian pharmaceutical company, Fidson Healthcare and Jiangsu Aidea Pharmaceutical Co. Ltd (Aidea Pharma), an innovative pharmaceutical company in China, have officially signed a strategic partnership agreement in China.